US 11,939,398 B2
Modified peptides for use in treating neurodegenerative disorders
Susan Greenfield, Abingdon (GB); Sara Garcia-Rates, Abingdon (GB); Jesus Seco Moral, Barcelona (ES); and Roger Prades Cosano, Barcelona (ES)
Assigned to Neuro-Bio Ltd, Abingdon (GB)
Appl. No. 16/325,716
Filed by Neuro-Bio Ltd, Abingdon (GB)
PCT Filed Aug. 16, 2017, PCT No. PCT/GB2017/052407
§ 371(c)(1), (2) Date Feb. 14, 2019,
PCT Pub. No. WO2018/033724, PCT Pub. Date Feb. 22, 2018.
Claims priority of application No. 1613999 (GB), filed on Aug. 16, 2016; and application No. 1701455 (GB), filed on Jan. 30, 2017.
Prior Publication US 2021/0094983 A1, Apr. 1, 2021
Int. Cl. C07K 5/08 (2006.01); A61P 25/28 (2006.01); C07K 5/087 (2006.01); C07K 5/09 (2006.01); C07K 5/097 (2006.01); A61K 38/00 (2006.01)
CPC C07K 5/0821 (2013.01) [A61P 25/28 (2018.01); C07K 5/0812 (2013.01); C07K 5/0817 (2013.01); A61K 38/00 (2013.01)] 7 Claims
 
1. A method of treating or ameliorating Alzheimer's disease, the method comprising administering, to a subject in need of such treatment, a therapeutically effective amount of a compound of Formula (I):

OG Complex Work Unit Chemistry
wherein:
R1 is —NR9R10 or —OH, either:

OG Complex Work Unit Chemistry
R4 is

OG Complex Work Unit Chemistry
and R6 is

OG Complex Work Unit Chemistry
(ii) R2 is

OG Complex Work Unit Chemistry
R4 is

OG Complex Work Unit Chemistry
and R6 is

OG Complex Work Unit Chemistry
R3, R5, and R7 are —H; R8 is

OG Complex Work Unit Chemistry
R9 and R10 arc —H;
R11 is an aryl group;
and
each n is 0, 1, 2, 3, or 4.